Xspray Pharma Q1’22: Truly Exciting Times Ahead - Redeye
Redeye leaves its view on Xspray following today’s Q1 report. We maintain our optimistic view of the case and reiterate our fair value range accordingly.
ANNONS
Redeye leaves its view on Xspray following today’s Q1 report. We maintain our optimistic view of the case and reiterate our fair value range accordingly.